Financials
Financial year 2025
EMMAGENICS from Gent, company number BE0786877064, closed financial year 2025 with a result of € 171,314 after tax. For that financial year EMMAGENICS recorded a gross margin of € 222,392 and equity of € 93,815. Compared with financial year 2024, the result moved from € -3,853 to € 171,314. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 93,815
▲ 237% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 171,314
▲ still € 3,853 loss in 2024
Profit after tax over the fiscal year.
€ 264,595
▲ 67% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 105,300 paid out
61 % of the profit went to the shareholders, mostly to MEDIFA (100 % of the shares). That is where the money ends up.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 22,871
▼ 74% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 82,921
▲ 145% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 36,484 | € -2,939 | € 222,392 | ▲ € 225,332 |
| Profit after taxes | € 26,654 | € -3,853 | € 171,314 | ▲ € 175,167 |
| Equity | € 31,654 | € 27,801 | € 93,815 | ▲ 237% |
| Total debts | € 270,876 | € 538,024 | € 549,280 | ▲ 2% |
| Cash | € 5,467 | € 158,721 | € 264,595 | ▲ 67% |
| Retained profit | € 26,654 | € 22,801 | € 88,815 | ▲ 290% |
| Dividend | € 0 | € 0 | € 105,300 | |
| Balance sheet total | € 302,530 | € 565,825 | € 643,095 | ▲ 14% |
Key figures of EMMAGENICS, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EMMAGENICS?
What happened at EMMAGENICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 171,314. Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Gent. KBO
- Medifa BV became a director. NBB
In short
From € 26,654 profit in 2023 to € 171,314 profit in 2025.
Paid € 48,779 in corporate taxes since 2023.
Best year ever: 2025, with € 171,314 profit.
Paid out € 105,300 in dividends to the owners in total.
Management
The stake of MEDIFA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EMMAGENICSBehind EMMAGENICS is Medifa BV. The shares are held by MEDIFA (100%).
Directors
According to the 2025 annual accounts
since 2022
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1202 box B/C
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- MEDIFA(oprichter) 100%
Details
- Company number
- 0786.877.064
- VAT number
- BE 0786.877.064
- Registered office
- Kortrijksesteenweg 1202 bus B/C, 9051 Gent
- Names & denominations
- EMMAGENICS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 June 2022
- Peppol
- Active · Active since 1 Sept 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Schoonheidsverzorging en andere schoonheidsbehandelingen
Markt- en opinieonderzoek
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Groothandel in parfumerieën en cosmetica
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
Schoonheidsverzorging
+1